Squamous Cell Carcinoma of Head and Neck
139
36
56
40
Key Insights
Highlights
Success Rate
66% trial completion
Published Results
18 trials with published results (13%)
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 59/100
15.1%
21 terminated out of 139 trials
65.6%
-20.9% vs benchmark
7%
10 trials in Phase 3/4
45%
18 of 40 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 40 completed trials
Clinical Trials (139)
A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer
A Phase I/II Trial of UCB4594 in Participants With Advanced Cancer
A Study of Amivantamab Alone or in Addition to Other Treatment Agents in Participants With Head and Neck Cancer
A Study of JNJ-90301900 in Combination With Chemoradiation Therapy in Participants With Locally Advanced Head and Neck Squamous Cell Carcinoma
HYPORT: A Phase I/II Study of Hypofractionated Post-operative Radiation Therapy for Head and Neck Cancer
A Study of Atezolizumab Plus Tiragolumab and Atezolizumab Plus Placebo as First-Line Treatment in Participants With Recurrent/Metastatic PD-L1 Positive Squamous Cell Carcinoma of the Head and Neck
5-Fluorouracil Response and Optimization STudy (The FROST Trial)
Trial of a Personalized and Adaptive Neoantigen Dose-Adjusted Vaccine Concurrently With Pembrolizumab
Pilot Study of Imatinib Cetuximab Combo for H & N Cancer
A Study Investigating the Efficacy and Safety of the Combination of Iparomlimab and Tuvonralimab With or Without Chemotherapy in Second-line and Subsequent Treatments for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
Neoadjuvant CADI-05 in Combination With Pembrolizumab for Surgically Resectable Locally Advanced Head and Neck Squamous Cell Carcinomas
A Study of BMS-986340 as Monotherapy and in Combination With Nivolumab or Docetaxel in Participants With Advanced Solid Tumors
Candida Therapeutic Vaccine in Head and Neck Cancer Patients to Reduce Recurrence
Camrelizumab in Combination With Cetuximab and Chemotherapy for Relapsed/Metastatic HNSCC Patients
TBio-4101 and Pembro wi/ or w/o Chemo in Recurrent/Metastatic HNSCC
Study of Xevinapant With Radiation and Chemotherapy for Patients With Head and Neck Cancer
Using MASL to Combat Oral Cancer
A Study of Head and Neck MRI and Tumor Microenvironment Biomarkers
HN-BIO 02: A Phase II Randomized Study of the Effects of Delayed Elective Radiotherapy on Head and Neck MRI and Immune Response Biomarkers